Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62016CA0329

Case C-329/16: Judgment of the Court (Fourth Chamber) of 7 December 2017 (request for a preliminary ruling from the Conseil d’État — France) — Syndicat national de l’industrie des technologies médicales (Snitem), Philips France v Premier ministre, Ministre des Affaires sociales et de la Santé (Reference for a preliminary ruling — Medical devices — Directive 93/42/EEC — Scope — ‘Medical device’ — CE marking — National legislation making drug prescription assistance software subject to a certification procedure laid down by a national authority)

OJ C 52, 12.2.2018, p. 7–8 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

12.2.2018   

EN

Official Journal of the European Union

C 52/7


Judgment of the Court (Fourth Chamber) of 7 December 2017 (request for a preliminary ruling from the Conseil d’État — France) — Syndicat national de l’industrie des technologies médicales (Snitem), Philips France v Premier ministre, Ministre des Affaires sociales et de la Santé

(Case C-329/16) (1)

((Reference for a preliminary ruling - Medical devices - Directive 93/42/EEC - Scope - ‘Medical device’ - CE marking - National legislation making drug prescription assistance software subject to a certification procedure laid down by a national authority))

(2018/C 052/09)

Language of the case: French

Referring court

Conseil d’État

Parties to the main proceedings

Applicants: Syndicat national de l’industrie des technologies médicales (Snitem), Philips France

Defendants: Premier ministre, Ministre des Affaires sociales et de la Santé

Operative part of the judgment

Article 1(1) and Article 1(2)(a) of Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, as amended by Directive 2007/47/EC of the European Parliament and of the Council of 5 September 2007, must be interpreted as meaning that software, of which at least one of the functions makes it possible to use patient-specific data for the purposes, inter alia, of detecting contraindications, drug interactions and excessive doses, is, in respect of that function, a medical device within the meaning of those provisions, even if that software does not act directly in or on the human body.


(1)  OJ C 296, 16.8.2016.


Top